|
|
Vertex Pharmaceuticals Inc (VRTX) |
|
Price: $347.0400
$-3.15 
-0.900%
|
| Day's High:
| $353.03
| Week Perf:
| -2.18 %
|
| Day's Low: |
$ 346.29 |
30 Day Perf: |
-2.32 % |
| Volume (M): |
1,154 |
52 Wk High: |
$ 387.42 |
| Volume (M$): |
$ 400,519 |
52 Wk Avg: |
$332.24 |
| Open: |
$350.32 |
52 Wk Low: |
$282.21 |
|
|
| Market Capitalization (Millions $) |
90,439 |
| Shares
Outstanding (Millions) |
261 |
| Employees |
3,900 |
| Revenues (TTM) (Millions $) |
9,654 |
| Net Income (TTM) (Millions $) |
3,470 |
| Cash Flow (TTM) (Millions $) |
1,940 |
| Capital Exp. (TTM) (Millions $) |
176 |
Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc. is a biotechnology company that focuses on discovering, developing, and commercializing innovative medicines for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Inc. has become a leading player in the field of cystic fibrosis, a genetic disease that affects the lungs and other organs. The company's first drug, Kalydeco, was approved in 2012 and was the first drug to treat the underlying cause of cystic fibrosis in patients with a specific genetic mutation. Since then, Vertex Pharmaceuticals Inc. has developed other drugs for cystic fibrosis, including Orkambi and Symdeko, which have greatly improved the lives of patients.
Aside from its work in cystic fibrosis, Vertex Pharmaceuticals Inc. is also exploring other therapeutic areas, including sickle cell disease, beta thalassemia, and pain management. The company's research and development efforts are focused on small molecules and gene therapies, with the goal of developing precision medicines that target the underlying cause of diseases.
In addition to its drug development efforts, Vertex Pharmaceuticals Inc. is committed to corporate social responsibility. The company has a strong commitment to environmental sustainability and works to reduce its carbon footprint through energy conservation, recycling, and sustainable building practices. The company is also committed to supporting patient advocacy groups and has established programs to help patients access its medications.
Overall, Vertex Pharmaceuticals Inc. is a company that is dedicated to developing innovative medicines for serious diseases, while also maintaining a strong commitment to corporate social responsibility. With its cutting-edge research, talented team of scientists and clinicians, and commitment to patients and the community, Vertex Pharmaceuticals Inc. is poised to continue making a significant impact in the field of biotechnology.
Company Address: 50 Northern Avenue Boston 2210 MA
Company Phone Number: 341-6100 Stock Exchange / Ticker: NASDAQ VRTX
| VRTX is expected to report next financial results on February 09, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Briacell Therapeutics Corp
The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.
|
|
Gt Biopharma Inc
The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
13.33 $ |
| Revenues (TTM) |
37.05 $
|
| Cash Flow (TTM) |
7.44 $ |
| Cash |
45.77 $
|
| Book Value |
63.36 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
13.33 $
|
| Revenues (TTM) |
37.05 $ |
| Cash Flow (TTM) |
7.44 $ |
| Cash |
45.77 $
|
| Book Value |
63.36 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
